河化股份(000953) - 2023 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2023 was ¥111,495,001.53, representing an increase of 18.72% compared to ¥93,912,016.56 in the same period last year[25]. - The net profit attributable to shareholders of the listed company decreased by 78.18% to ¥356,658.48 from ¥1,634,818.67 in the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥544,314.27, a significant increase of 116.29% compared to a loss of ¥3,340,425.88 in the same period last year[25]. - Basic and diluted earnings per share both decreased by 77.78% to ¥0.0010 from ¥0.0045 in the same period last year[25]. - The company reported a total profit of ¥754,299.40, a significant decline of 75.2% from ¥3,033,844.18 in the first half of 2022[133]. - The comprehensive income for the current period is CNY 590,111.63, compared to CNY 1,999,808.03 in the same period last year, indicating a decrease of approximately 70.5%[143]. Cash Flow and Investments - The net cash flow from operating activities was ¥1,685,641.76, down 86.40% from ¥12,395,475.38 in the previous year[25]. - The net increase in cash and cash equivalents was negative at ¥-2,779,232.88, a decline of 109.26% compared to the previous year[45]. - The cash flow from investment activities showed a net outflow of ¥4,405,627.69, compared to a net inflow of ¥17,542,602.30 in the first half of 2022[138]. - Cash received from tax refunds was ¥436,952.04, down from ¥2,502,372.12 in the previous year, indicating a decrease of 82.5%[138]. - The company reported cash outflows for employee payments totaling ¥12,956,390.60, an increase of 6.3% from ¥12,192,234.30 in the same period last year[138]. Assets and Liabilities - Total assets at the end of the reporting period were ¥290,238,680.79, an increase of 1.23% from ¥286,706,539.83 at the end of the previous year[25]. - Total liabilities increased to CNY 194,976,587.27 from CNY 192,258,417.77, marking a growth of approximately 0.9%[129]. - The company's equity attributable to shareholders increased to CNY 78,405,721.41 from CNY 77,839,963.09, a rise of approximately 0.7%[129]. - The total owner's equity as of June 30, 2023, was CNY 95,262,093.52, compared to CNY 94,448,122.06, indicating a growth of about 0.9%[129]. Business Operations - The main business activities include the research, production, and sales of pharmaceutical intermediates and the commissioned processing and sales of urea[31]. - The pharmaceutical intermediate business generated a revenue of 39.2191 million yuan, a significant year-on-year growth of 62.08%[41]. - The urea business reported a revenue of 71.5864 million yuan, reflecting a year-on-year increase of 3.87%[42]. - The company completed the development of 9 projects and has 3 projects under research, with 5 pilot projects completed and 4 small-scale projects finished[43]. - The company has established long-term cooperation with major raw material suppliers to mitigate the impact of seasonal fluctuations in raw material supply[34]. Environmental and Safety Management - The company emphasizes environmental, health, and safety (EHS) management across all business operations, enhancing sustainable development[39]. - The company has a waste gas treatment facility with a design capacity of 15,000 m³/h for workshop 1 and 25,000 m³/h for workshop 2, ensuring compliance with emission standards[76]. - The company reported no significant environmental violations during the reporting period, maintaining compliance with pollution discharge standards[73]. - The company has established a self-monitoring plan and has reported no exceedances in pollutant levels during monitoring[79]. Shareholder and Governance - The company emphasizes the protection of shareholder rights, particularly for minority shareholders, and maintains transparent communication through various channels[81]. - The company has not engaged in any significant litigation or arbitration matters during the reporting period[90]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[86]. - The total number of ordinary shareholders at the end of the reporting period is 24,007[114]. - The largest shareholder, Ningbo Yinyi Holdings Co., Ltd., holds 23.76% of the shares, totaling 87,000,000 shares, which are currently frozen[114]. Research and Development - Research and development expenses increased by 46.99% to ¥2,891,612.18, primarily due to an increase in R&D projects[45]. - The company continues to focus on the research and development of chemical raw materials and biopharmaceuticals, aiming to enhance its market position[150]. Financial Reporting and Compliance - The financial report for the first half of 2023 has not been audited[125]. - The financial statements comply with the relevant accounting standards and accurately reflect the company's financial position as of June 30, 2023[157]. - The company’s financial statements are prepared based on the going concern assumption, with no significant doubts regarding its ability to continue operations[156].